Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 19, 2026 (Updated: November 19, 2026)

Pyxis’ Matrix-Targeting ADC MICVO Shows 39% Response Rate and 9.2-Month Median Response Duration in Previously Treated Head and Neck Cancer

Listen
0:00 / 0:00

Key Takeaways

  • MICVO targets EDB+ fibronectin, a tumor neovasculature–associated extracellular matrix antigen largely absent in normal adult tissue, enabling a non-cellular ADC approach with potential stromal and immunomodulatory effects.
  • Updated phase 1 outcomes at capped 5.4 mg/kg Q3W showed 39% cORR, 94% disease control, 6.7-month median PFS, and 81% 12-month OS probability in 2L+ R/M HNSCC.
SHOW MORE

Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.

Micvotabart pelidotin (MICVO; Pyxis Oncology) achieved a 39% confirmed objective response rate (cORR) and a median duration of response of 9.2 months in previously treated patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), according to updated phase 1 data that Pyxis announced on November 18, 2026.¹ Faye Johnson, MD, PhD, professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, presented the results on November 19 in a late-breaking oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.¹

How does MICVO work?

MICVO is built around a non-cellular target. The antibody-drug conjugate (ADC) binds extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix, and Pyxis describes it as a first-in-concept ADC.¹ The company says MICVO is designed to kill cancer cells directly, reduce extracellular matrix density, inhibit tumor angiogenesis, and mobilize an antitumor immune response.¹

The extra domain B of fibronectin is rarely found in healthy adults and is expressed almost exclusively by newly formed blood vessels in tumors, according to a 2020 review in Molecular Oncology.² In a study of 82 head and neck biopsy specimens, the domain stained strongly in 87% of the 53 malignant tumors, less often in benign and nontumoral lesions, and not at all in normal control tissue.³

Where an ADC releases its payload is a central design question for the modality. In a BioPharm International® Q&A, Paul Romness, chair, chief executive officer, and president of OS Therapies, said, “The linker is responsible for ensuring the payload reaches the tumor while limiting exposure to healthy tissue.”

What did the updated analysis show?

As of an October 14, 2026, data cutoff, the 33 efficacy-evaluable patients, all dosed at 5.4 mg/kg intravenously every three weeks at or below a dose cap, had a 94% disease control rate, a median progression-free survival (PFS) of 6.7 months, and a 12-month overall survival probability of 81%.¹ At the prior August 18 cutoff, Pyxis had reported a 36% cORR and a median PFS of 6.2 months.⁴

The cORR was 41% in HPV-positive disease (n = 17) and 38% in HPV-unrelated disease (n = 16). It was 33% in patients previously treated with an EGFR inhibitor (n = 18) vs 47% in those who were not (n = 15).¹ In a new intrapatient comparison, median PFS on MICVO was 6.7 months (95% CI, 4.8-9.0) vs 4.2 months (95% CI, 2.8-5.6) on patients’ most recent prior therapy.¹

On safety, Tom Civik, chief executive officer and chairman of Pyxis Oncology, said that “there have been no new cases of Grade 3 peripheral neuropathy and the six patients that experienced Grade 3 peripheral neuropathy have all improved with five of the six patients resolving to Grade 1 or better.”¹ Among patients dosed above a cap for men heavier than 80 kg and women heavier than 70 kg (n = 9), 56% discontinued for treatment-related adverse events and 67% had grade 3 treatment-related peripheral neuropathy, compared with 20% and 0%, respectively, among patients who received the capped dose (n = 5).¹

Why is this population hard to treat?

Between 60% and 80% of patients with advanced HNSCC progress after first-line immune checkpoint inhibitor-based therapy, and there is no universally accepted standard of care after progression on PD-1/PD-L1 inhibitors, according to a 2025 review in Cancers.⁵ In the pre-immunotherapy era, second-line systemic therapies achieved a median PFS of 2.2 months and a median overall survival of 6.1 months.⁵ The FDA recently granted accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma.

“For patients whose disease progresses after platinum chemotherapy and immunotherapy, there remains a substantial unmet medical need, particularly as we anticipate broader use of EGFR-targeted therapies in earlier lines of treatment,” Johnson said.¹

What happens next?

Pyxis plans to start the global phase 3 Headliner trial in second-line and later R/M HNSCC in mid-2027, with more mature overall survival data expected in the first half of 2027.¹ MICVO holds FDA Fast Track designation for adults with R/M HNSCC that has progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy.¹ The results come from a single-arm phase 1 study, and several subgroups include fewer than 20 patients.¹

References

  1. Pyxis Oncology. Pyxis Oncology to host live webcast on updated MICVO phase 1 monotherapy data demonstrating durable response in 2L+ R/M HNSCC following late-breaking oral presentation at EORTC-NCI-AACR Symposium. News release. GlobeNewswire. Published November 18, 2026. Accessed November 19, 2026.
  2. Lieverse RIY, Marcus D, van der Wiel AMA, et al. Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Mol Oncol. 2020;14(7):1555-1568. doi:10.1002/1878-0261.12705
  3. Birchler MT, Milisavlijevic D, Pfaltz M, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope. 2003;113(7):1231-1237. doi:10.1097/00005537-200307000-00023
  4. Pyxis Oncology. Pyxis Oncology announces positive updated data from phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). News release. Published September 9, 2026. Accessed November 19, 2026.
  5. Abraham FF, Julian R. Emerging and investigational systemic therapies in recurrent/metastatic head and neck cancer after progression on immunotherapy. Cancers (Basel). 2025;17(23):3817. doi:10.3390/cancers17233817

Related to this article